Kevin Ali, Organon CEO

Organon inks $103M deal for per­tuzum­ab and deno­sum­ab biosim­i­lars

Organon is look­ing to boost its biosim­i­lar port­fo­lio with two well-known brand copies in de­vel­op­ment by Shang­hai-based Hen­lius Biotech.

The women’s health phar­ma is pay­ing $73 mil­lion up­front, plus up to $30 mil­lion in 2022 mile­stone pay­ments, for the per­tuzum­ab biosim­i­lar to Roche’s Genen­tech’s breast can­cer drug Per­je­ta and the deno­sum­ab biosim­i­lar to Am­gen’s Pro­lia for os­teo­poro­sis and Xge­va for bone prob­lem pre­ven­tion in can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.